Mineralys Therapeutics, Inc. (MLYS) annual balance sheet — 6-year assets, liabilities & equity history
| Total Current Assets | 652.47M | 661.39M | 205.35M | 249.1M | 112.81M | 11.12M | 1.47M |
| Cash & Short-Term Investments | 646.06M | 656.63M | 198.19M | 236.57M | 110.11M | 10.61M | 1.41M |
| Cash Only | 112.78M | 172.92M | 114.09M | 49.3M | 87.7M | 10.61M | 1.41M |
| Short-Term Investments | 533.28M | 483.71M | 84.1M | 187.26M | 22.41M | 0 | 0 |
| Accounts Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Sales Outstanding | - | - | - | - | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - |
| Other Current Assets | 6.41M | 4.75M | 7.16M | 12.54M | 2.7M | 0 | 0 |
| Total Non-Current Assets | 392K | 420K | 552K | 2.53M | 1.63M | 3K | 20K |
| Property, Plant & Equipment | 32K | 38K | 53K | 0 | 0 | 0 | 0 |
| Fixed Asset Turnover | 0.00x | - | - | - | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 2.48M | 0 | 0 | 0 |
| Other Non-Current Assets | 360K | 382K | 499K | 51K | 1.63M | 3K | 20K |
| Total Assets | 652.86M | 661.81M | 205.9M | 251.64M | 114.44M | 11.13M | 1.49M |
| Asset Turnover | 0.00x | - | - | - | - | - | - |
| Asset Growth % | 434.41% | 221.42% | -18.17% | 119.88% | 928.69% | 648.65% | - |
| Total Current Liabilities | 14.72M | 15.11M | 14.65M | 10.48M | 8.07M | 5.05M | 5.08M |
| Accounts Payable | 1.12M | 2.02M | 479K | 601K | 1.91M | 763K | 529K |
| Days Payables Outstanding | 32.23K | - | - | - | - | - | - |
| Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 4.5M |
| Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 11.29M | 7.56M | 0 | 1.6M | 665K | 313K | 0 |
| Current Ratio | 44.33x | 43.76x | 14.02x | 23.76x | 13.98x | 2.20x | 0.29x |
| Quick Ratio | 44.33x | 43.76x | 14.02x | 23.76x | 13.98x | 2.20x | 0.29x |
| Cash Conversion Cycle | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 0 | 0 | 0 | 0 | 158.64M | 29M | 0 |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 158.64M | 29M | 0 |
| Total Liabilities | 14.72M | 15.11M | 14.65M | 10.48M | 166.71M | 34.05M | 5.08M |
| Total Debt | 0 | 0 | 0 | 0 | 0 | 0 | 4.5M |
| Net Debt | -112.78M | -172.92M | -114.09M | -49.3M | -87.7M | -10.61M | 3.09M |
| Debt / Equity | 0.00x | - | - | - | - | - | - |
| Debt / EBITDA | -0.00x | - | - | - | - | - | - |
| Net Debt / EBITDA | 0.66x | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | -18.78x | -717.81x | -28.79x |
| Total Equity | 638.14M | 646.69M | 191.26M | 241.15M | -52.27M | -22.93M | -3.6M |
| Equity Growth % | 476.34% | 238.13% | -20.69% | 561.37% | -128% | -537.34% | - |
| Book Value per Share | 7.70 | 9.56 | 3.94 | 6.66 | -10.12 | -4.60 | -0.78 |
| Total Shareholders' Equity | 638.14M | 646.69M | 191.26M | 241.15M | -52.27M | -22.93M | -3.6M |
| Common Stock | 8K | 8K | 5K | 4K | 1K | 1K | 1K |
| Retained Earnings | -496.51M | -457.17M | -302.52M | -124.71M | -52.81M | -23.01M | -3.6M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | -251.64M | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying MLYS stock.
As of 2025, Mineralys Therapeutics, Inc. (MLYS) had total assets of $661.8M including $661.4M in current assets.
Mineralys Therapeutics, Inc. (MLYS) carries total debt of $0.0M, offset by $656.6M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Mineralys Therapeutics, Inc. (MLYS) has total shareholders' equity (book value) of $646.7M ($9.56 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Mineralys Therapeutics, Inc. (MLYS) reported a current ratio of 43.76x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.